# Biotech Daily Digest — 2025-11-08

**7 items from 2 sources**

## Summary by Source

- Endpoints News: 5 items
- Fierce Biotech: 2 items


## Endpoints News

- **[Updated: Pfizer triumphs over Novo Nordisk with $10B bid for Metsera](https://endpoints.news/pfizer-triumphs-over-novo-nordisk-with-10b-bid-for-metsera/)**  
  _Sat, 08 Nov 2025 09:36:54 +0000_  
  Pfizer has won the bidding war for the obesity drug developer Metsera. The biotech accepted an increased bid from the New York pharma worth a total of $10 billion.

 Late Friday night, Metsera

- **[CMS unveils new Medicaid drug payment model](https://endpoints.news/cms-unveils-new-medicaid-drug-payment-model/)**  
  _Fri, 07 Nov 2025 20:56:28 +0000_  
  CMS plans to launch a new drug payment model for state Medicaid programs, the first of potentially multiple pricing models under President Donald Trump's "most favored nation" push that the pharma industry has been closely ...

- **[Gilead’s Trodelvy fails Phase 3 breast cancer study](https://endpoints.news/gileads-trodelvy-fails-phase-3-breast-cancer-study/)**  
  _Fri, 07 Nov 2025 20:02:05 +0000_  
  Gilead’s Trodelvy failed to meet the primary endpoint in a Phase 3 trial for certain breast cancer patients, marking another setback for a key drug in Gilead’s cancer portfolio.

 Trodelvy has faced a series of ...

- **[Sana suspends work on allogeneic CAR-T; Biokin eyes $387M raise in Hong Kong](https://endpoints.news/sana-suspends-work-on-allogeneic-car-t-biokin-eyes-387m-raise-in-hong-kong/)**  
  _Fri, 07 Nov 2025 15:27:39 +0000_  
  Plus, news about Codexis, Gilead, nChroma Bio, Bavarian Nordic, UroGen, Agenus, Accipiter Biosciences and Immunocore:

 ✂️ Sana trims cell therapy pipeline: The Seattle-based biotech is

- **[ObesityWeek rode the momentum of the field's most dramatic week in months](https://endpoints.news/obesityweek-rode-the-waves-of-the-fields-most-dramatic-week-in-months/)**  
  _Fri, 07 Nov 2025 14:30:19 +0000_  
  ATLANTA — At one of the main annual gatherings of researchers and drug developers in the obesity field, Novo Nordisk and Eli Lilly were the talk of the town.

 But it wasn't just because of their ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/pfizer-beats-out-novo-10b-agreement-buy-metsera" hreflang="en">Pfizer beats out Novo with $10B agreement to buy Metsera</a>](https://www.fiercebiotech.com/biotech/pfizer-beats-out-novo-10b-agreement-buy-metsera)**  
  _Nov 8, 2025 8:02am_  
  After a chaotic and fierce bidding clash that only burst out into the public view a little more than a week ago, Pfizer has prevailed in its pursuit of obesity biotech Metsera.

- **[<a href="https://www.fiercebiotech.com/biotech/amid-metsera-contest-novo-ceo-tells-pfizer-bid-higher-if-it-wants-win" hreflang="en">Amid Metsera wrestling match, Novo CEO touts 'higher' bid and goads Pfizer</a>](https://www.fiercebiotech.com/biotech/amid-metsera-contest-novo-ceo-tells-pfizer-bid-higher-if-it-wants-win)**  
  _Nov 7, 2025 9:21am_  
  Amid Novo Nordisk and Pfizer’s whiplash bidding war for obesity biotech Metsera, Novo’s CEO has, quite literally, told its rival to put its money where its mouth is.
